Vikki Conway Biography and Net Worth

Acting Head of Global Human Resources of Teva Pharmaceutical Industries

Vikki Conway was appointed as acting Head of Global Human Resources in September 2023. Vikki joined Teva over a decade ago and has held various HR leadership roles, most recently as HRBP in Global R&D and prior to that in Global Marketing, based in West Chester, US. She has provided HR leadership in business transformations and played a pivotal role in several past R&D business development acquisitions.

In this current role she oversees Teva's global human capital strategy, shapes Teva's culture, and designs best practices and processes to maintain Teva as a strong and attractive employer of choice and to enable the skills needed to allow Teva to achieve its goals.

Teva employs around 37,000 employees in 60 markets. This diverse employee base works to provide 3,500 different products to nearly 200 million people every day. Teva's global HR group works in close partnership with the business leaders to strengthen the organization’s performance by translating business needs into people strategy, and by leading all organizational and employee aspects including talent management, employee experience, diversity and inclusion, wellbeing, learning and development, and total rewards.

Prior to joining Teva in 2010, Vikki held related leadership roles at Cephalon Pharmaceuticals, Digitas Health and Medical Broadcasting Company.

What is Vikki L. Conway's net worth?: The estimated net worth of Vikki L. Conway is at least $64,679.52 as of February 28th, 2024. Ms. Conway owns 2,928 shares of Teva Pharmaceutical Industries stock worth more than $64,680 as of December 21st. This net worth evaluation does not reflect any other investments that Ms. Conway may own. Learn More about Vikki L. Conway's net worth.
How do I contact Vikki L. Conway?: The corporate mailing address for Ms. Conway and other Teva Pharmaceutical Industries executives is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. Teva Pharmaceutical Industries can also be reached via phone at (723) 914-8213 and via email at [email protected]. Learn More on Vikki L. Conway's contact information.
Has Vikki L. Conway been buying or selling shares of Teva Pharmaceutical Industries?: Vikki L. Conway has not been actively trading shares of Teva Pharmaceutical Industries during the past quarter. Most recently, Vikki L. Conway sold 15,219 shares of the business's stock in a transaction on Monday, May 13th. The shares were sold at an average price of $16.74, for a transaction totalling $254,766.06. Learn More on Vikki L. Conway's trading history.
Who are Teva Pharmaceutical Industries' active insiders?: Teva Pharmaceutical Industries' insider roster includes Vikki Conway (Acting Head of Global Human Resources), Rosemary Crane (Director), Richard Daniell (VP), Sven Dethlefs (EVP), Eric Drape (VP), Christine Fox (EVP, U.S. Commercial), Richard Francis (President, CEO & Director), Hafrun Fridriksdottir (VP), Eric Hughes (insider), Eliyahu Kalif (CFO), Roberto Mignone (Director), Mark Sabag (Insider), Eli Shani (EVP), David Stark (VP), and Amir Weiss (CAO). Learn More on Teva Pharmaceutical Industries' active insiders.
Are insiders buying or selling shares of Teva Pharmaceutical Industries?: During the last twelve months, insiders at the sold shares 11 times. They sold a total of 984,382 shares worth more than $15,236,840.56. The most recent insider tranaction occured on November, 20th when EVP Christine Fox sold 19,388 shares worth more than $327,075.56. Insiders at Teva Pharmaceutical Industries own 0.6% of the company. Learn More about insider trades at Teva Pharmaceutical Industries.
Information on this page was last updated on 11/20/2024.

Vikki L. Conway Insider Trading History at Teva Pharmaceutical Industries

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/13/2024	Sell	15,219	$16.74	$254,766.06
2/28/2024	Sell	1,366	$13.12	$17,921.92	2,928

Vikki L. Conway Buying and Selling Activity at Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Company Overview

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Today's Range

Now: $22.09

$21.11

$22.17

50 Day Range

MA: $17.79

$16.44

$22.09

2 Week Range

Now: $22.09

$10.34

$22.17

Volume

12,760,563 shs

Average Volume

9,444,773 shs

Market Capitalization

$25.03 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.79

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...

I put all the details together for you here — but please hurry.